SAN DIEGO, Oct. 13, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the closing of its previously announced underwritten public offering of 2,475,248 shares of its common stock, plus 277,389 additional shares sold pursuant to the underwriter's partial exercise of its option to purchase additional shares, each at a price to the public of $10.10 per share. Including this option exercise, the gross proceeds to Cidara from…

SAN DIEGO, Oct. 07, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of an underwritten public offering of 2,475,248 shares of its common stock at a price to the public of $10.10 per share. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $25.0 million. The offering is expected to close…

SAN DIEGO, Oct. 06, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has commenced an underwritten public offering of its common stock. Cidara also expects to grant the underwriter of the offering a 30-day option to purchase additional shares of its common stock at the public offering price. The offering is subject to market conditions, and there can be no assurance as to whether or…

CD201 Demonstrates Potential to Treat Life-Threatening Multi-Drug Resistant Gram-negative Bacterial Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has selected the first development candidate from its proprietary immunotherapy discovery platform, Cloudbreak™. Cloudbreak is the first platform of its kind designed specifically to create compounds that direct a patient's immune cells to attack and eliminate bacterial, fungal or viral microbial pathogens. The…

SAN DIEGO, Sept. 20, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 28, 2016. Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 3:05 p.m. EDT (12:05 p.m. PDT). The conference is being held in…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced that the company has named Taylor Sandison, M.D., M.P.H., its vice president, clinical development, to the position of acting chief medical officer, effective September 2, 2016. Dr. Sandison will replace Dirk Thye, M.D., Cidara's previous chief medical officer, who has accepted a CEO position at a non-competing San Francisco Bay Area-based biotech…

SAN DIEGO, Aug. 11, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months ended June 30, 2016 and provided an update on its corporate activities and product pipeline. "Cidara has made notable clinical progress in the second quarter and subsequently as we dosed the first patients in our STRIVE and RADIANT Phase 2 trials of CD101.…

Presentations Will Highlight Data from Studies of Novel Echinocandin CD101 and Reinforce the Unmet Need for Effective New VVC Treatments SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical studies evaluating its novel Phase 2 echinocandin CD101 as a topical treatment for vulvovaginal candidiasis (VVC) will be presented at the annual meeting of the Infectious Diseases Society…

SAN DIEGO, July 06, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the 2nd Annual Cantor Fitzgerald Healthcare Conference on Tuesday, July 12, 2016. Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 9:30 a.m. EDT (6:30 a.m. PDT). The conference is being held in New York City. A live…

SAN DIEGO, July 05, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the addition of Neil Abdollahian and Matt Onaitis to the executive management team. Mr. Abdollahian joins as Chief Business Officer and Mr. Onaitis will assume the role of Chief Financial Officer and General Counsel. Previously, Mr. Abdollahian was Vice President of Corporate Development and Mr. Onaitis was General Counsel…